STML Stemline Therapeutics Inc.

11.25
+0.50  (5%)
Previous Close 10.75
Open 10.90
Price To book 3.56
Market Cap 284400270
Shares 25,280,024
Volume 268,116
Short Ratio 9.75
Av. Daily Volume 166,686

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 ongoing. ASH oral presentation - December 2016. Update due later in 2017.
SL-401
High Risk Myeloproliferative Neoplasms
Phase 2 enrollment completed - noted March 23, 2017. Update on patients enrolled in Stages 1 and 2 at EHA June 23, 2017 with top-line data from Stage 3 due 2H 2017.
SL-401
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) cancer
Phase 2 preliminary data released November 2016.
SL-701
Second line glioblastoma (GBM) cancer
Phase 2 ongoing. ASH oral presentation - December 2016. Update due later in 2017.
SL-401
Cancer- adult relapsed or refractory acute myeloid leukemia (AML)

Latest News

  1. Stemline Therapeutics to Present at Upcoming Investor Conferences
  2. Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017
  3. Stemline Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
  4. ETFs with exposure to Stemline Therapeutics, Inc. : September 1, 2017
  5. Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress
  6. Stemline Therapeutics, Inc. :STML-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  7. Stemline Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
  8. Stemline Therapeutics reports 2Q loss
  9. Stemline Therapeutics Reports Second Quarter 2017 Financial Results
  10. Stemline Therapeutics Presents SL-401 Updated Stage 1 and 2 Data from Ongoing Pivotal Trial in BPDCN and Safety Experience Across Multiple Indications, Today at EHA
  11. Implied Volatility Surging for Stemline Therapeutics (STML) Stock Options
  12. Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc.
  13. J&W Investigates Investment Technology Group (ITG) and Stemline Therapeutics (STML); Should Officers and Directors be Responsible for Alleged Harm to the Company?
  14. DEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
  15. FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline: April 4, 2017